Botulinum toxin type A + Placebo

Phase 3Completed

0 views this week 0 watching💤 Quiet

Interest: 37/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Cerebral Palsy

Conditions

Cerebral Palsy, Muscle Spasticity, Children

Trial Timeline

Jul 1, 2011 → Jun 1, 2014

NCT ID

NCT01249417

About Botulinum toxin type A + Placebo

Botulinum toxin type A + Placebo is a phase 3 stage product being developed by Ipsen for Cerebral Palsy. The current trial status is completed. This product is registered under clinical trial identifier NCT01249417. Target conditions include Cerebral Palsy, Muscle Spasticity, Children.

What happened to similar drugs?

5 of 16 similar drugs in Cerebral Palsy were approved

Approved (5) Terminated (1) Active (11)

✅mouse nerve growth factorSun PharmaceuticalApproved

✅RosuvastatinAstraZenecaApproved

✅clopidogrel (SR25990C)SanofiApproved

✅PiracetamUCBApproved

✅Baclofen, Diazepam, Clonazepam, Trihexyphenidyl, Tetrabenazine, Gabapentin, Topiramate, Lamotrigine, Amitriptyline.Brain BiotechApproved

🔄Oral Glycopyrrolate LiquidShionogiPhase 3

🔄NXY-059AstraZenecaPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (14)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03569098	Phase 2	Completed	Jun 19, 2018	May 22, 2020	Hallux Abducto Valgus
NCT03598777	Phase 2	Terminated	Jun 11, 2018	Jan 21, 2021	Vulvodynia
NCT02493946	Phase 3	Completed	Apr 1, 2015	Dec 1, 2016	Glabellar Lines
NCT02353871	Phase 3	Completed	Jan 1, 2015	Aug 1, 2015	Moderate to Severe Glabellar Lines
NCT02321436	Approved	Completed	Dec 1, 2014	Mar 1, 2016	Stroke
NCT01753310	Phase 3	Completed	Jan 1, 2013	Jan 1, 2015	Cervical Dystonia
NCT01249417	Phase 3	Completed	Jul 1, 2011	Jun 1, 2014	Cerebral Palsy
NCT01357980	Phase 2	Completed	May 1, 2011	Mar 1, 2013	Detrusor Muscle Hyperactivity
NCT01249404	Phase 3	Completed	Mar 1, 2011	May 1, 2014	Leg Spasticity
NCT00578097	Phase 2	Terminated	Feb 1, 2008	Dec 1, 2009	Overactive Bladder
NCT00257660	Phase 3	Completed	Oct 10, 2005	Sep 1, 2006	Cervical Dystonia
NCT00447876	Phase 2/3	Completed	Jul 1, 2005	Apr 1, 2009	Chronic Plantar Fasciitis
NCT00216411	Approved	Completed	Nov 1, 2004	Jul 20, 2006	Cerebrovascular Accident
NCT00234546	Approved	Completed	Feb 1, 2003	Oct 1, 2007	Muscle Spasticity

Competing Products

20 competing products in Cerebral Palsy

See all competitors

Product	Company	Stage	Hype Score
mouse nerve growth factor	Sun Pharmaceutical	Approved	39
Edaravone Dexborneol + Placebo	Sun Pharmaceutical	Phase 2	31
Oral Glycopyrrolate Liquid	Shionogi	Phase 3	40
recombinant human erythropoietin alfa + 0.9% NaCl	Johnson & Johnson	Phase 2/3	38
UDI-001	Rohto Pharmaceutical	Phase 1/2	32
NXY-059	AstraZeneca	Phase 3	40
NXY-059	AstraZeneca	Phase 2	35
Rosuvastatin	AstraZeneca	Approved	39
NXY-059	AstraZeneca	Phase 3	40
Comparator: Placebo + Comparator: MK0724	Merck	Phase 2	27
Vorapaxar 2.5 mg + Vorapaxar 1 mg + Placebo + Aspirin 75-150 mg	Merck	Phase 2	35
Recombinant Factor VIIa + Biological/Vaccine: Placebo	Novo Nordisk	Phase 3	47
Recombinant Activated Factor VII (rFVIIa) + Placebo	Novo Nordisk	Phase 3	44
Ponezumab	Pfizer	Phase 2	35
PF-05230907	Pfizer	Phase 1	21
Azithromycin + Pyrimethamine + Leucovorin calcium	Pfizer	Phase 1	29
clopidogrel (SR25990C)	Sanofi	Approved	43
Intrarectal quinine	Sanofi	Phase 3	36
Piracetam	UCB	Approved	35
Placebo + ALN-APP	Alnylam Pharmaceuticals	Phase 2	39